Trial record 1 of 1 for:
inovatyon
INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer (INOVATYON)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01379989 |
|
Recruitment Status :
Completed
First Posted : June 23, 2011
Last Update Posted : February 9, 2022
|
Sponsor:
Mario Negri Institute for Pharmacological Research
Collaborators:
PharmaMar
Averion International Corporation
Information provided by (Responsible Party):
Mario Negri Institute for Pharmacological Research
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The objective of this multicentric, randomised, Phase III study is to demonstrate superiority, in terms of survival, of trabectedin and Pegylated Liposomal Doxorubicin (PLD) versus carboplatin and PLD in partially-platinum sensitive ovarian cancer patients.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Ovarian Cancer | Drug: Carboplatin Drug: Pegylated Lipoxomal Doxorubicin (PLD) Drug: Trabectedin | Phase 3 |
Patients will be randomised to:
Arm A: PLD 30 mg/m2 and carboplatin AUC 5; Arm B: PLD 30 mg/m2 and trabectedin 1.1 mg/m2. Patients' characteristics: patients over 18 years of age with advanced, progressive ovarian cancer 6-12 months after completion of first line or second line treatment with platinum-based chemotherapy.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 617 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Phase III International, Randomized Study of Trabectedin Plus Pegylated Liposomal Doxorubicin (PLD) Versus Carboplatin Plus PLD in Patients With Ovarian Cancer Progressing Within 6-12 Months of Last Platinum |
| Study Start Date : | June 2011 |
| Actual Primary Completion Date : | December 17, 2020 |
| Actual Study Completion Date : | December 17, 2020 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Ovarian cancer
MedlinePlus related topics:
Ovarian Cancer
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Carboplatin plus PLD
Pegylated Lipoxomal Doxorubicin (PLD) 30 mg/ m2 followed by carboplatin AUC 5.
|
Drug: Carboplatin
Carboplatin AUC 5
Other Name: Carboplatin generic Drug: Pegylated Lipoxomal Doxorubicin (PLD) PLD 30 mg/m² i.v.
Other Name: Caelyx |
|
Experimental: Trabectedin plus PLD
Pegylated Lipoxomal Doxorubicin (PLD) 30 mg/m2 infusion followed by trabectedin 1.1 mg/m2 infusion.
|
Drug: Pegylated Lipoxomal Doxorubicin (PLD)
PLD 30 mg/m² i.v.
Other Name: Caelyx Drug: Trabectedin trabectedin 1.1 mg/m2 3-hour i.v. infusion on Day 1 every 3 weeks. The use of central venous access is strongly recommended.
Other Name: Yondelis |
Primary Outcome Measures :
- Overall survival (OS) [ Time Frame: This outcome measure will be assess approximately 4.5-5 years after the last patient enrolled ]This is an event driven study. The study will continue until 442 events have occurred.
Secondary Outcome Measures :
- Progression Free Survival (PFS) [ Time Frame: This outcome measure will be assess approximately 4.5-5 years after the last patient enrolled, at the same time points of the Primary Endpoint ]PFS will be measured from the date of randomization to the date of documented PD or death (regardless of cause of death).
- Objective RR [ Time Frame: This outcome measure will be assess approximately 4.5-5 years after the last patient enrolled, at the same time points of the Primary Endpoint ]Objective RR will be the best response obtained in any evaluation according to RECIST 1.1
- CA-125 serological response [ Time Frame: This outcome measure will be assess approximately 4.5-5 years after the last patient enrolled, at the same time points of the Primary Endpoint ]CA-125 serological response will be the best response obtained in each arm
- Duration of Response [ Time Frame: This outcome measure will be assess approximately 4.5-5 years after the last patient enrolled, at the same time points of the Primary Endpoint ]Duration of response: will be calculated from the date of first documentation of response (CR or partial response [PR], whichever occurs first) to the date of documented PD or death.
- Time to subsequent chemotherapy administration [ Time Frame: This outcome measure will be assess approximately 4.5-5 years after the last patient enrolled, at the same time points of the Primary Endpoint ]The time from randomization to subsequent chemotherapy counted from the administration of subsequent chemotherapy will be evaluated as an exploratory analysis.
- OS for Subsequent chemotherapies [ Time Frame: This outcome measure will be assess approximately 4.5-5 years after the last patient enrolled, at the same time points of the Primary Endpoint ]the overall survival counted from the administration of subsequent chemotherapy until death
- PFS for the Subsequent Chemotherapies [ Time Frame: This outcome measure will be assess approximately 4.5-5 years after the last patient enrolled, at the same time points of the Primary Endpoint ]the progression free survival counted from the administration of subsequent chemotherapy untill disease progression or death whichever occurs first
- Frequency of serious adverse events (SAEs) [ Time Frame: This outcome measure will be assess approximately 4.5-5 years after the last patient enrolled, at the same time points of the Primary Endpoint ]Number of SAEs for each randomization arm
- QoL according to the EORTC QLQ-C30 and QLQ-OV28 [ Time Frame: This outcome measure will be assess approximately 4.5-5 years after the last patient enrolled, at the same time points of the Primary Endpoint ]Two PRO instruments will be administered in this study: the EORTC QLQ-C30 and QLQ-OV28.PRO instruments will be completed by the patient at screening (before randomization) and within four weeks after the 6th cycle or at the time of progression, whichever occurs first.
- Best response to each Subsequent chemotherapy line [ Time Frame: This outcome measure will be assess approximately 4.5-5 years after the last patient enrolled, at the same time points of the Primary Endpoint ]The best response obtained to each Subsequent chemotherapy line calculated as frequency of patients with CR, PR, SD or PD.
- Frequency of toxicities, graded according to the NCI-CTAE version 4.0 [ Time Frame: This outcome measure will be assess approximately 4.5-5 years after the last patient enrolled, at the same time points of the Primary Endpoint ]Clinical and laboratory toxicities
- Frequency of toxicities leading to dose delays [ Time Frame: This outcome measure will be assess approximately 4.5-5 years after the last patient enrolled, at the same time points of the Primary Endpoint ]Clinical and laboratory toxicities
- Frequency of toxicities leading to dose modifications [ Time Frame: This outcome measure will be assess approximately 4.5-5 years after the last patient enrolled, at the same time points of the Primary Endpoint ]Clinical and laboratory toxicities
- Frequency of toxicities leading to treatment discontinuation [ Time Frame: This outcome measure will be assess approximately 4.5-5 years after the last patient enrolled, at the same time points of the Primary Endpoint ]Clinical and laboratory toxicities
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Female, aged ≥ 18 years
- Histologically and/or cytologically proven epithelial ovarian, epithelial fallopian tube cancer or primary peritoneal cancer
- Progression free interval between six and twelve (6-12) months (calculated from the first day of the last cycle of the last platinum-based chemotherapy until the date of progression confirmation through radiologic imagery). Patients may have received up to two platinum-based chemotherapy lines, of which at least one must have contained a taxane
- Measurable or evaluable disease confirmed by radiological imaging, such as magnetic resonance imaging (MRI), computed tomography (CT) scan, or PET/CT scan at study entry (CA-125 rise not supported by radiological evidence of disease is not accepted as criteria for defining progression) or histological proven recurrent ovarian cancer even in the absence of postoperatively measurable or evaluable lesions.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2
- Estimated life expectancy ≥ 12 weeks
- Patients must be accessible for treatment and follow-up
- Adequate organ function within 14 days prior to first cycle as evidenced
- Patients must be able to receive dexamethasone or its equivalent, which is required if randomly assigned to treatment with trabectedin plus PLD
- Informed consent of the patient
Exclusion Criteria:
- Non epithelial ovarian or mixed epithelial/non epithelial tumors (e.g., Mullerian tumors)
- Patients who did not respond to last platinum-based therapy or in whom last relapse occurred < 6 months or > 12 months from the last dose of platinum
- Bowel obstruction, sub-occlusive disease or the presence of symptomatic brain metastases
- Pre-existing grade > 1 motor or sensory neuropathy according to the National Cancer Institute Common Toxicity Criteria Adverse Event (NCI-CTCAE) version 4.0
- Myocardial infarct within six months before enrolment, New York Association (NYHA) Class II or worse heart failure (Appendix 1. The New York Heart Association), uncontrolled angina, severe uncontrolled ventricular arrythmias, clinically significant pericardial disease, or electrocardiographic evidence of acute ischemic or active conduction system abnormalities
- History of liver disease
- Concurrent severe medical problems or any unstable medical condition unrelated to malignancy, which would significantly limit full compliance with the study or expose the patient to extreme risk or decreased life expectancy
- Breastfeeding women and women of child bearing potential must use effective contraception during treatment and 3 months thereafter, which may include prescription contraceptives (oral, injection, or patch), intrauterine device, double-barrier method or male partner sterilization (not applicable to patients that are surgically sterile)
- Prior exposure to trabectedin
- Prior resistance to anthracyclines or PLD defined as a progression during anthracycline-based chemotherapy or a recurrence within 6 months from its ending
- Prior severe PLD related toxicity
- Prior exposure to cumulative doses of doxorubicin >400mg/m2 or epirubicin >720mg/m2
- Treatment with any investigational product within 30 days prior to inclusion in the study
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01379989
Locations
Show 132 study locations
Sponsors and Collaborators
Mario Negri Institute for Pharmacological Research
PharmaMar
Averion International Corporation
Investigators
| Principal Investigator: | Nicoletta Colombo, MD | European Institute of Oncology (I.E.O), Milan, Italy |
| Responsible Party: | Mario Negri Institute for Pharmacological Research |
| ClinicalTrials.gov Identifier: | NCT01379989 |
| Other Study ID Numbers: |
ET-D-009-10 |
| First Posted: | June 23, 2011 Key Record Dates |
| Last Update Posted: | February 9, 2022 |
| Last Verified: | February 2022 |
Additional relevant MeSH terms:
|
Ovarian Neoplasms Carcinoma, Ovarian Epithelial Endocrine Gland Neoplasms Neoplasms by Site Neoplasms Ovarian Diseases Adnexal Diseases Genital Diseases, Female Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Genital Neoplasms, Female Urogenital Neoplasms Genital Diseases Endocrine System Diseases |
Gonadal Disorders Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Carboplatin Doxorubicin Trabectedin Antineoplastic Agents Antibiotics, Antineoplastic Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents, Alkylating Alkylating Agents |